Overview

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their current regimen.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Anticonvulsants
Etiracetam
Lacosamide
Piracetam